[go: up one dir, main page]

MX2009012203A - Treatment of duchenne muscular dystrophy. - Google Patents

Treatment of duchenne muscular dystrophy.

Info

Publication number
MX2009012203A
MX2009012203A MX2009012203A MX2009012203A MX2009012203A MX 2009012203 A MX2009012203 A MX 2009012203A MX 2009012203 A MX2009012203 A MX 2009012203A MX 2009012203 A MX2009012203 A MX 2009012203A MX 2009012203 A MX2009012203 A MX 2009012203A
Authority
MX
Mexico
Prior art keywords
muscular dystrophy
treatment
duchenne muscular
compounds
duchenne
Prior art date
Application number
MX2009012203A
Other languages
Spanish (es)
Inventor
Graham Michael Wynne
Richard Storer
Stephen Paul Wren
Peter David Johnson
Olivier De Moor
Renate Van Well
Cristina Lecci
Severine Poignant
Original Assignee
Summit Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp Plc filed Critical Summit Corp Plc
Publication of MX2009012203A publication Critical patent/MX2009012203A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings
    • C07F9/65324—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

There are disclosed compounds of Formula (1). Pharmaceutical compositions containing the compounds are also provided. Methods of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy and cachexia using the compounds and compositions are also provided.
MX2009012203A 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy. MX2009012203A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0715939.5A GB0715939D0 (en) 2007-08-15 2007-08-15 Method of treatment of duchenne muscular dystrophy
PCT/EP2008/006720 WO2009021750A2 (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
MX2009012203A true MX2009012203A (en) 2009-12-18

Family

ID=38566449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012203A MX2009012203A (en) 2007-08-15 2008-08-14 Treatment of duchenne muscular dystrophy.

Country Status (8)

Country Link
JP (1) JP2010535831A (en)
CN (1) CN102036972A (en)
AU (1) AU2008286326A1 (en)
CA (1) CA2685605A1 (en)
GB (1) GB0715939D0 (en)
MX (1) MX2009012203A (en)
TW (1) TW200914430A (en)
WO (1) WO2009021750A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905667D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
DK2835131T3 (en) * 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
US9246108B2 (en) * 2012-12-28 2016-01-26 Dow Global Technologies Llc Quinoline-benzoxazole derived compounds for electronic films and devices
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
AU2017243198A1 (en) * 2016-03-30 2018-11-22 Summit (Oxford) Limited Composition for the treatment of duchenne muscular dystrophy
CN116472269A (en) * 2020-09-11 2023-07-21 加利福尼亚大学董事会 Compositions and methods for treating muscular dystrophy
IL301122A (en) * 2020-09-11 2023-05-01 Univ California Preparations and methods for the treatment of muscular dystrophy
CN113264894A (en) * 2021-05-24 2021-08-17 陕西维世诺新材料有限公司 Benzoxazole derivative and preparation method thereof
US20250205247A1 (en) 2022-03-15 2025-06-26 Centre D'etude Des Cellules Souches Use of bazedoxifene for increasing muscle survival

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
EP1460067A4 (en) * 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVE, PROCESS FOR PRODUCTION OF THE DERIVATIVE, AND USE THEREOF
US6960607B2 (en) * 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
CA2496633A1 (en) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
WO2004041277A1 (en) * 2002-11-01 2004-05-21 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
EP1454627A1 (en) * 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
SI1986633T1 (en) * 2006-02-10 2015-03-31 Summit Corporation Plc Treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
CA2685605A1 (en) 2009-02-19
AU2008286326A1 (en) 2009-02-19
TW200914430A (en) 2009-04-01
CN102036972A (en) 2011-04-27
WO2009021750A3 (en) 2014-02-20
JP2010535831A (en) 2010-11-25
GB0715939D0 (en) 2007-09-26
WO2009021750A2 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
MX2009012203A (en) Treatment of duchenne muscular dystrophy.
MX2009012558A (en) Drug combinations for the treatment of duchenne muscular dystrophy.
WO2009019505A3 (en) Drug combinations for the treatment of duchenne muscular dystrophy
MX2010003155A (en) Cyclopropyl aryl amide derivatives and uses thereof.
MY153915A (en) Organic compounds
MX2010003156A (en) Tetrazole-substituted aryl amide derivatives and uses thereof.
WO2010020432A3 (en) Compounds for treatment of duchenne muscular dystrophy
WO2009121623A3 (en) Compounds for treating muscular dystrophy
MY180812A (en) 4'-o-substituted isoindoline derivattives and compositions comprising and methods of using the same
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
SI1853602T1 (en) Chemical compounds
PT1853588E (en) Chemical compounds
MX2012002759A (en) Chemical compounds.
MY151986A (en) Adamantyl diamide derivatives and uses of same
MY148634A (en) Pyridazinone derivatives
MX2011011661A (en) Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750.
TNSN07322A1 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
GEP201706703B (en) Boronate ester compounds and pharmaceutical compositions thereof
MX2010003366A (en) Piperidine and piperazine derivatives for treating tumours.
MX2010003868A (en) Chiral cis-imidazolines.
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
MX2012002366A (en) Novel pyrrolidine derived beta 3 adrenergic receptor agonists.
MX2010003368A (en) Imidazole derivatives.
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones

Legal Events

Date Code Title Description
HC Change of company name or juridical status